MRNA · Earnings event · Q2 2026 · archived
Moderna (MRNA) Q2 2026 earnings — TrendMatrix coverage
Reported · EPS $-1.97 vs estimate $-2.06 (+4.3%) — classified BEAT.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Event detail · Q2 2026
EPS beat/miss and revenue
| Metric | Estimate | Actual | Surprise |
|---|---|---|---|
| EPS (diluted) | $-2.06 | $-1.97 | +4.3% |
| Revenue (2026-06-30) | — | $145.0M | — |
Revenue source: xbrl.
Verdict reaction
How the verdict moved around this report
Before this report, TrendMatrix rated MRNA Data Issue at 4.6/10. After the Q2 2026 report, the verdict moved to Sell at 4.5/10.
Healthcare context
MRNA at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $25.28B
- P/E (fwd)
- -12.9
- 52-week range
- $22.28–$85.60
- Off 52-week high
- 26.1%
- RSI (14)
- 66
- Volume vs avg
- 0.87×
- Engine score
- 4.1/10
Live context at TrendMatrix’s latest engine read — updates after the report date; not frozen to it.